YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.

Trial Details

NCT ID
NCT07461454
Phase
PHASE3
Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • YL202
  • Eribulin
  • Capecitabine
  • Gemcitabine
  • Vinorelbine
  • Sacituzumab govitecan
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form.
  • Histologically and/or cytologically confirmed locally advanced or metastatic HR+/HER2- breast cancer who are not candidates for curative surgery or…
  • Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage.
  • Have at least 1 extracranial measurable lesion as a target lesion per RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →